← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 INmune Bio INMB $44.4M	7	+2	+40%	$375K
102	102 DELISTED Scorpius Holdings, Inc. SCPX	7	+1	+17%	$1.3M
103	103 DELISTED DermTech, Inc. Common Stock DMTK	5	0	0%	$8.22M
104	104 Genprex GNPX $1.79M	5	+1	+25%	$2.52M
105	105 iShares Genomics Immunology and Healthcare ETF IDNA $306M	4	+4	–	$6.68M
106	106 Global X Genomics & Biotechnology ETF GNOM $95.9M	3	+3	–	$415K
107	107 Enlivex Ltd ENLV $4.31M	2	+1	+100%	$461K
108	ACHL 108 DELISTED Achilles Therapeutics ACHL	–	–	–	–
109	109 DELISTED Arcellx ACLX	–	–	–	–
110	AKUS 110 DELISTED Akouos Inc AKUS	–	–	–	–
111	111 ALPS Group Inc ALPS $55.4M	–	–	–	–
112	112 Artiva Biotherapeutics ARTV $294M	–	–	–	–
113	113 BioCardia BCDA $13.8M	–	–	–	–
114	114 Beam Therapeutics BEAM $2.42B	–	–	–	–
115	115 Burning Rock Biotech BNR $154M	–	–	–	–
116	116 BioRestorative Therapies BRTX $2.13M	–	–	–	–
117	117 Cabaletta Bio CABA $241M	–	–	–	–
118	118 Candel Therapeutics CADL $644M	–	–	–	–
119	119 Caris Life Sciences CAI $8.75B	–	–	–	–
120	120 CAMP4 Therapeutics CAMP $210M	–	–	–	–
121	121 Celularity CELU $40.9M	–	–	–	–
122	122 Creative Medical Technology CELZ $6.02M	–	–	–	–
123	123 DELISTED CERo Therapeutics CERO	–	–	–	–
124	124 Calidi Biotherapeutics CLDI $2.21M	–	–	–	–
125	125 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–